» Articles » PMID: 36696881

Albumin-myosteatosis Gauge As a Novel Prognostic Risk Factor in Patients with Non-metastatic Colorectal Cancer

Overview
Date 2023 Jan 25
PMID 36696881
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Myosteatosis and systemic inflammation are well-known prognostic factors in patients with colorectal cancer (CRC). The serum albumin level is a reflection of malnutrition and systemic inflammation, which in turn plays a key role in the development of myosteatosis. However, few studies have been conducted on these synergistic effects. This study aimed to examine the individual and synergistic effects of different prognostic markers related to skeletal muscle quality and serum albumin levels in patients with CRC.

Methods: This study enrolled patients with stage I-III CRC who underwent surgical resection between July 2006 and February 2014. Skeletal muscle index (SMI) and skeletal muscle radiodensity (SMD) were calculated using computed tomography at the L3 level obtained within 2 months prior to surgery. The albumin-myosteatosis gauge (AMG) was defined as SMD × albumin. Patients were divided into sex-specific quartiles (G1 to G4) according to the AMG, and analysis of variance for continuous variables and chi-square test for categorical variables were used to compare variables among quartiles. Cox proportional hazard models were constructed and integrated receiver operating characteristic curve (iAUC) analysis was used to compare the prognostic performance of SMD, albumin and AMG.

Results: Among the 906 participants, the median (interquartile) age was 64 (55-72) years, and 365 (40.3%) were female. AMG was significantly correlated with the occurrence of complications, albumin level, SMI and SMD (all P < 0.001). Overall survival (OS) differed significantly according to the AMG group, with 5-year OS for G1-G4 being 73.4%, 86.2%, 91.1% and 95.5%, respectively (P < 0.0001). Although SMI, SMD, albumin and AMG were all significant individual prognostic markers of OS in the univariable analysis, AMG remained the only independent prognostic factor in the multivariable analysis (G1 vs. G2, P = 0.045, G1 vs. G3, P = 0.005, G1 vs. G4, P < 0.001, respectively). The iAUC value of AMG [0.681, 95% confidence interval (CI) = 0.638-0.723] was superior to that of SMD (0.610, 95% CI = 0.566-0.654) (bootstrap iAUC mean difference = 0.071, 95% CI = 0.034-0.106), SMI (0.551, 95% CI = 0.511-0.594) (bootstrap iAUC mean difference = 0.129, 95% CI = 0.076-0.181) and albumin (0.627, 95% CI = 0.585-0.668) (bootstrap iAUC mean difference = 0.053, 95% CI = 0.010-0.098).

Conclusions: In patients with stage I-III CRC, AMG is a meaningful predictor of survival, with superior prognostic value compared to SMI, SMD or albumin alone. Further studies are needed to determine their significance in different ethnic groups.

Citing Articles

Postoperative Changes in Body Composition Predict Long-Term Prognosis in Patients with Gastric Cancer.

Shuto K, Nabeya Y, Mori M, Yamazaki M, Kosugi C, Narushima K Cancers (Basel). 2025; 17(5).

PMID: 40075586 PMC: 11898653. DOI: 10.3390/cancers17050738.


Development of a predictive nomogram based on preoperative inflammation-nutrition-related markers for prognosis in locally advanced lip squamous cell carcinoma after surgical treatment.

Cheng H, Xu X, Zhang Z, Xu J, Li Z, Wang Y BMC Oral Health. 2025; 25(1):268.

PMID: 39979915 PMC: 11843749. DOI: 10.1186/s12903-025-05663-6.


A Nomogram for Predicting Overall Survival in Primary Central Nervous System Lymphoma: A Retrospective Study.

Ling Y, Miao X, Zhou X, Ma J, Lin Z, Li Q J Inflamm Res. 2025; 18:2091-2103.

PMID: 39959640 PMC: 11827503. DOI: 10.2147/JIR.S498121.


Albumin-muscle density score predicts overall survival in patients with hepatocellular cancer undergoing treatment with transarterial chemoembolization.

Surov A, Wienke A, Borggrefe J, Auer T, Gebauer B, Mahringer-Kunz A J Cancer Res Clin Oncol. 2024; 150(12):515.

PMID: 39614916 PMC: 11608168. DOI: 10.1007/s00432-024-06043-3.


Strength in quality: Myosteatosis as a predictor of survival in advanced hepatocellular carcinoma.

Campani C, Berzigotti A United European Gastroenterol J. 2024; 12(8):1002-1003.

PMID: 39095956 PMC: 11485297. DOI: 10.1002/ueg2.12645.


References
1.
Kasprzak A . The Role of Tumor Microenvironment Cells in Colorectal Cancer (CRC) Cachexia. Int J Mol Sci. 2021; 22(4). PMC: 7913937. DOI: 10.3390/ijms22041565. View

2.
McGovern J, Dolan R, Horgan P, Laird B, McMillan D . Computed tomography-defined low skeletal muscle index and density in cancer patients: observations from a systematic review. J Cachexia Sarcopenia Muscle. 2021; 12(6):1408-1417. PMC: 8718024. DOI: 10.1002/jcsm.12831. View

3.
Baumgartner R, Koehler K, Gallagher D, Romero L, Heymsfield S, Ross R . Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998; 147(8):755-63. DOI: 10.1093/oxfordjournals.aje.a009520. View

4.
Ahn H, Kim D, Ko Y, Ha J, Shin Y, Lee J . Updated systematic review and meta-analysis on diagnostic issues and the prognostic impact of myosteatosis: A new paradigm beyond sarcopenia. Ageing Res Rev. 2021; 70:101398. DOI: 10.1016/j.arr.2021.101398. View

5.
Martin L, Birdsell L, MacDonald N, Reiman T, Clandinin M, McCargar L . Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013; 31(12):1539-47. DOI: 10.1200/JCO.2012.45.2722. View